VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be added to the Russell 2000(R) Index effective Monday, June 28, 2021. The company will be added to the index at the conclusion of the 2021 Russell Indexes annual reconstitution. Investment managers and institutional investors often use the Russell U.S. Indexes, which are part of global index provider FTSE Russell, as a basis for index funds and as benchmarks for active investment strategies. According to the announcement, an estimated $10.6 trillion in assets are benchmarked against Russell U.S. Indexes. When a company is selected to join the all-cap Russell 3000(R) Index, the company is also automatically included in the large-cap Russell 1000(R) Index or small-cap Russell 2000)R Index, along with other appropriate growth- and value-style indexes. “Inclusion in the Russell 2000 Index, which is one of the most cited performance benchmarks for small-cap companies, is another important milestone for VistaGen and an achievement we expect will increase overall awareness and exposure of our company within the investment community,” said VistaGen CEO Shawn K. Singh. “Our late-stage anxiety and depression programs have exciting potential to change lives. We look forward to introducing our company to a wider investor audience as we continue to execute on noteworthy milestones during the second half of the year and beyond.”
To view the full press release, visit https://ibn.fm/K310x
About VistaGen Therapeutics Inc.
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
